Metronomic chemotherapy from rationale to clinical studies: a dream or reality?
about
The Promise of Preventive Cancer VaccinesSchedule-Dependent Antiangiogenic and Cytotoxic Effects of Chemotherapy on Vascular Endothelial and Retinoblastoma CellsMetronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.Immunotherapeutic approaches for hepatocellular carcinomaThird-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study.Primary atypical teratoid/rhabdoid tumor of the spine in an adult patient.Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study.Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine - a Phase I trial.Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice.Application of Evolutionary Principles to Cancer TherapyMetronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.Current achievements and future perspectives of metronomic chemotherapy.Novel 20(S)-sulfonylamidine derivatives of camptothecin and the use thereof as a potent antitumor agent: a patent evaluation of WO2015048365 (A1).Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial.CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study.Anti-angiogenic and anti-tumor effects of metronomic use of novel liposomal zoledronic acid depletes tumor-associated macrophages in triple negative breast cancer.Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key.Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting.
P2860
Q26783742-1C8BF015-B09B-4A1C-846E-3A0540EB7C75Q28553176-13DDD0A0-B58F-4079-8028-80F83845F09BQ30846827-A65C8F0E-1D52-480F-A510-13026C56B5A2Q33779723-7A8D787F-944D-4E5D-AFDE-7A4E70EDD177Q36421012-6775BF70-C0CB-4D53-9163-6D557C797C18Q36715435-D67D6BF4-B05C-4EE6-BBF9-FD345C9F7B50Q37637994-88C3AD90-1088-4DCA-AC63-1E19FDEF066EQ37669505-81E06E9F-E76E-4031-9BD0-F5AB2BAD94BCQ37731326-BC1F9E21-E600-4FCF-B722-7629CF711CD9Q38623060-D2DCF18F-E3E3-4DA1-8B40-D00A7A8EE0AEQ38638654-2B23D25D-48BA-494F-BF9F-769C54FDB654Q38757723-3BB35CA9-303A-4E29-94B7-07489ED3C593Q38788234-A5585128-27A3-489B-A725-CD66DD489896Q38799252-628C4AC0-24DF-4ABC-87B4-D7E5678DA659Q40657628-833CB429-864B-42AC-9A6C-C99305D03C21Q46085386-6052BD20-692A-4B52-BF90-D28B5C6239FCQ47101676-F810EA3E-904E-4D3E-8957-9484E41ED040Q47103586-12E33CEB-220A-42A9-971A-C0FE9EACE194Q48344360-3DCFB592-DCA4-4B29-92FF-034D10DD3F5EQ48505173-F99B8263-BA62-4434-8868-E5FAC36E0305
P2860
Metronomic chemotherapy from rationale to clinical studies: a dream or reality?
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Metronomic chemotherapy from rationale to clinical studies: a dream or reality?
@en
type
label
Metronomic chemotherapy from rationale to clinical studies: a dream or reality?
@en
prefLabel
Metronomic chemotherapy from rationale to clinical studies: a dream or reality?
@en
P2093
P50
P1476
Metronomic chemotherapy from rationale to clinical studies: a dream or reality?
@en
P2093
Angelo Vacca
Antonella Licchetta
Antonio Gnoni
Fausto Petrelli
Nicola Silvestris
Salvatore Pisconti
Vito Lorusso
P356
10.1016/J.CRITREVONC.2015.01.008
P577
2015-01-20T00:00:00Z